KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

• click to rate

  Posted by Two Blokes Jun 25 - Filed in Stock - 2 views
  
  Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.